Seald AS is a biotech company developing an innovative live and personalised medical diagnostic for treating solid cancer using bile duct cancer as a working model. As each patient is unique, so is their cancer. The method is an advanced decision tool that aims to identify the best cancer drug in the optimal dose for each individual, avoiding non-effective cancer treatment which potentially only adds side effects.
Investigations reveal that most cancer drugs do not lead to beneficial treatment effect for several of the cancer patients treated with the drug. These groups of none-responders lack a diagnostic method that reveals which drug to take and which to avoid.
Our working model bile duct cancer, cholangiocarcinoma, is a rare, but very deadly form of cancer. The five year survival is two to five per cent, the mean life expectancy on standard chemotherapy is only 11,5 months. A small number of patients are eligible for surgery, and more than 50 per cent of these relapse. There is a huge unmet need for our diagnostic that pinpoints the right patient to the right drug.
Welcome to Seald AS
Addressing uncertainty. Unravelling cures.
Seald AS is a biotech company developing an innovative personalised diagnostic approach for treating solid cancers, using bile duct cancer as our working model. Bile duct cancer is a rare, but very deadly form of cancer afflicting three per cent of people with cancer in the digestive system. Utilising a whole new approach, Seald AS aspires to find the right treatment for the individual patient based on a methodology combining molecular biomarkers, DNA sequencing, ex-vivo drug sensitivity analysis, patient own live cancer cells and living xenograft animal models. Together with our research partners Institute of Cancer Research, The Radium Hospital, Seald plan to run the first clinical study at the renowned Norwegian Radium Hospital in 2020.
Renowned partnersRecognised scientific actors on board
Innovative approachTo quickly identify effective treatment using evidence-based tests using the patients own living cancer cells
Unmet medical needBile duct cancer is aggressiv and many patients, both with bile duct cancer and cancers in general, are treated with therapies that do not work
Large, global marketEstimated global pharma market is USD 2,1–4,2 billion, in addition to the markets for diagnostics and platform technology.I
Innovative therapies for bile duct cancer
The company develops novel therapies for bile duct cancer, also called cholangiocarcinoma (CCA). This is done by employing a multidisciplinary approach to developing completely personalised cures, through unraveling both new diagnostics, medications and a new method for personalised treatments.
Clinical trial to start in 2020
Clinical development will be conducted in collaboration with both Norwegian and American clinical research centres, and will be succeeded with an interventional study. These trials will be conducted at the Clinical Cancer Research Unit (Phase I unit) at the Norwegian Radium Hospital, Oslo University Hospital.